Immune Checkpoint Inhibitors for Hepatobiliary Cancers

Join us for this dynamic, case-based, CME-certified symposium, in which an expert panel will discuss current best practices and emerging strategies in using immune checkpoint inhibitors to treat patients with hepatocellular carcinoma. Sign up now!

Not an official event of the 2021 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

Immunotherapy for First-line Advanced HCC: Current Evidence and Ongoing Trials

Immunotherapy Combinations for Early or Intermediate-Stage HCC: Emerging Strategies

Immune Checkpoint Inhibitors for Biliary Tract Cancers

Events

Date / Time
Event Details

Faculty

Faculty
R. Kate Kelley, MD

Associate Professor
Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

Faculty
Amit Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging therapies into the treatment of patients with HCC and BTC.

Target Audience
This educational program is intended for medical oncologists, hepatologists, radiation oncologists, surgical oncologists, and other healthcare providers who treat patients with HCC and BTC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with hepatobiliary cancer most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Evaluate clinical data on the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC or BTC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.